{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:26:45Z","timestamp":1790638005124,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Clin Psychopharmacol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Preclinical evidence indicates that the \u03ba-opioid receptor (KOR)\/dynorphin pathway is implicated in depressive-like behaviors. Ketamine is believed to partly exert its antidepressant effects by modulating the opioid system. This post hoc study examined the following research questions: (1) at baseline, were there differences in KOR or dynorphin plasma levels between individuals with major depressive disorder (MDD) and healthy volunteers (HVs) or between men and women? (2) in individuals with MDD, did KOR or dynorphin baseline plasma levels moderate ketamine's therapeutic effects or adverse effects? and (3) in individuals with MDD, were KOR or dynorphin plasma levels affected after treatment with ketamine compared with placebo?<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Thirty-nine unmedicated individuals with MDD (23 women) and 25 HVs (16 women) received intravenous ketamine (0.5 mg\/kg) and placebo in a randomized, crossover, double-blind trial. Blood was obtained from all participants at baseline and at 3 postinfusion time points (230 minutes, day 1, day 3). Linear mixed model regressions were used.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At baseline, participants with MDD had lower KOR plasma levels than HVs (F<\/jats:italic>\n 1,60<\/jats:sub> = 13.16, P<\/jats:italic> < 0.001), and women (MDD and HVs) had higher KOR plasma levels than men (F<\/jats:italic>\n 1,60<\/jats:sub> = 4.98, P<\/jats:italic> = 0.03). Diagnosis and sex had no significant effects on baseline dynorphin levels. Baseline KOR and dynorphin levels did not moderate ketamine's therapeutic or adverse effects. Compared with placebo, ketamine was not associated with postinfusion changes in KOR or dynorphin levels.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In humans, diagnosis of MDD and biological sex are involved with changes in components of the KOR\/dynorphin pathway. Neither KOR nor dynorphin levels consistently moderated ketamine's therapeutic effects or adverse effects, nor were levels altered after ketamine infusion.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n NCT00088699 (ClinicalTrials.gov).<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/jcp.0000000000001663","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:07:39Z","timestamp":1677172059000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["\u03ba-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine"],"prefix":"10.1097","volume":"43","author":[{"given":"Brandi","family":"Quintanilla","sequence":"first","affiliation":[{"name":"Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo C.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dede","family":"Greenstein","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixiong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenessa N.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence T.","family":"Park","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando S.","family":"Goes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7412","authenticated-orcid":false,"given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib2-20250528","first-page":"627","article-title":"STAR*D: revising conventional wisdom","volume":"23","year":"2009","journal-title":"CNS Drugs"},{"key":"bib3-20250528","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","year":"2006","journal-title":"Am J Psychiatry"},{"key":"bib4-20250528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.12.018","article-title":"The International Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment","volume":"61","year":"2015","journal-title":"J Psychiatr Res"},{"key":"bib5-20250528","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"bib6-20250528","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"bib7-20250528","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","article-title":"Ketamine and the future of rapid-acting antidepressants","volume":"17","year":"2021","journal-title":"Annu Rev Clin Psychol"},{"key":"bib8-20250528","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","article-title":"Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches","volume":"24","year":"2019","journal-title":"Mol Psychiatry"},{"key":"bib9-20250528","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","year":"2013","journal-title":"Trends Neurosci"},{"key":"bib10-20250528","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"bib11-20250528","doi-asserted-by":"crossref","first-page":"114892","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"bib12-20250528","first-page":"170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","year":"2014","journal-title":"Front Psychiatry"},{"key":"bib13-20250528","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","year":"2010","journal-title":"Brain Res"},{"key":"bib15-20250528","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","year":"2016","journal-title":"Am J Psychiatry"},{"key":"bib16-20250528","first-page":"466","article-title":"Sex differences in kappa opioid receptor function and their potential impact on addiction","volume":"9","year":"2015","journal-title":"Front Neurosci"},{"key":"bib17-20250528","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","volume":"25","year":"2020","journal-title":"Mol Psychiatry"},{"key":"bib18-20250528","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/NDT.S199245","article-title":"Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)","volume":"15","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"bib19-20250528","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1017\/neu.2019.47","article-title":"In major depression, increased kappa and mu opioid receptor levels are associated with immune activation","volume":"32","year":"2020","journal-title":"Acta Neuropsychiatr"},{"key":"bib20-20250528","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2013.07.042","article-title":"Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats","volume":"76","year":"2014","journal-title":"Biol Psychiatry"},{"key":"bib21-20250528","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fphar.2018.00093","article-title":"Sex differences in the effects of a kappa opioid receptor antagonist in the forced swim test","volume":"9","year":"2018","journal-title":"Front Pharmacol"},{"key":"bib22-20250528","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","article-title":"Sex differences in neural mechanisms mediating reward and addiction","volume":"44","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"bib23-20250528","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1172\/JCI70395","article-title":"Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression","volume":"123","year":"2013","journal-title":"J Clin Invest"},{"key":"bib24-20250528","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.mp.4000930","article-title":"Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex","volume":"7","year":"2002","journal-title":"Mol Psychiatry"},{"key":"bib25-20250528","doi-asserted-by":"crossref","first-page":"e22042","DOI":"10.1002\/syn.22042","article-title":"Kappa opioid receptor binding in major depression: a pilot study","volume":"72","year":"2018","journal-title":"Synapse"},{"key":"bib26-20250528","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0361-9230(01)00525-1","article-title":"Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders","volume":"55","year":"2001","journal-title":"Brain Res Bull"},{"key":"bib27-20250528","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","year":"2021","journal-title":"Am J Psychiatry"},{"key":"bib28-20250528","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","year":"2018","journal-title":"Mol Psychiatry"},{"key":"bib29-20250528","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","year":"2018","journal-title":"Am J Psychiatry"},{"key":"bib30-20250528","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib31-20250528","doi-asserted-by":"crossref","first-page":"173228","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"bib32-20250528","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","year":"2021","journal-title":"Mol Psychiatry"},{"key":"bib33-20250528","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors","volume":"1562","year":"2014","journal-title":"Brain Res"},{"key":"bib34-20250528","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","year":"2018","journal-title":"Pharmacol Rev"},{"key":"bib35-20250528","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","year":"2019","journal-title":"Mol Psychiatry"},{"key":"bib37-20250528","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"Suppl 16","key":"bib38-20250528","first-page":"10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bib39-20250528","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale","volume":"167","year":"1995","journal-title":"Br J Psychiatry"},{"key":"bib40-20250528","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jrp.2005.11.001","article-title":"Anticipatory and consummatory components of the experience of pleasure: a scale development study","volume":"40","year":"2006","journal-title":"J Res Pers"},{"key":"bib41-20250528","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","year":"1959","journal-title":"Br J Med Psychol"},{"key":"bib42-20250528","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0005-7967(96)00033-2","article-title":"Psychometric properties of the PTSD Checklist (PCL)","volume":"34","year":"1996","journal-title":"Behav Res Ther"},{"key":"bib43-20250528","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","year":"1998","journal-title":"J Trauma Stress"},{"key":"bib44-20250528","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","year":"2020","journal-title":"J Affect Disord"},{"key":"bib45-20250528","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","year":"1962","journal-title":"Psychol Rep"},{"key":"bib46-20250528","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","year":"1978","journal-title":"Br J Psychiatry"},{"key":"bib48-20250528","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/01621459.1990.10474920","article-title":"Unmasking multivariate outliers and leverage points","volume":"85","year":"1990","journal-title":"J Am Stat Assoc"},{"key":"bib49-20250528","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: circuitry and implications for treatment","volume":"62","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"bib51-20250528","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","article-title":"Kappa opioid receptor distribution and function in primary afferents","volume":"99","year":"2018","journal-title":"Neuron"},{"issue":"Suppl 10","key":"bib52-20250528","first-page":"S10","article-title":"Delta and kappa opioid receptors as suitable drug targets for pain","volume":"26","year":"2010","journal-title":"Clin J Pain"},{"key":"bib53-20250528","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbi.2005.02.002","article-title":"Multiple opioid receptors on immune cells modulate intracellular signaling","volume":"20","year":"2006","journal-title":"Brain Behav Immun"},{"key":"bib54-20250528","doi-asserted-by":"crossref","first-page":"107638","DOI":"10.1016\/j.drugalcdep.2019.107638","article-title":"Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: possible role as a biomarker in severe opioid use disorder","volume":"205","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"bib55-20250528","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2174\/138945012799201612","article-title":"Current research on opioid receptor function","volume":"13","year":"2012","journal-title":"Curr Drug Targets"},{"key":"bib56-20250528","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1755-8794-1-41","article-title":"A high confidence, manually validated human blood plasma protein reference set","volume":"1","year":"2008","journal-title":"BMC Med Genomics"},{"key":"bib57-20250528","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1373\/clinchem.2009.126706","article-title":"The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum","volume":"56","year":"2010","journal-title":"Clin Chem"},{"key":"bib58-20250528","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nn.4409","article-title":"The road to precision psychiatry: translating genetics into disease mechanisms","volume":"19","year":"2016","journal-title":"Nat Neurosci"},{"key":"bib59-20250528","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/mp.2012.105","article-title":"Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it","volume":"17","year":"2012","journal-title":"Mol Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000001663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:06:12Z","timestamp":1748448372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000001663","relation":{},"ISSN":["1533-712X","0271-0749"],"issn-type":[{"value":"1533-712X","type":"electronic"},{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}